TipRanks
Go Ultimate55% OFF

Compare Viking Therapeutics (1VT) vs. Competitors

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
DE:1VTViking TherapeuticsEUR 24.00EUR 3.11B-4.97-26.38%Strong BuyUnlock the DE:1VT analyst price target with TipRanks PremiumDE:1VTUnlock the DE:1VT top-analyst price target with TipRanks Premium
NAMSNewAmsterdam Pharma Company$19.97$2.40B-8.97-48.46%Strong BuyUnlock the NAMS analyst price target with TipRanks PremiumDE:1VT vs NAMSUnlock the NAMS top-analyst price target with TipRanks Premium
MLYSMineralys Therapeutics, Inc.$16.03$1.61B-3.67-61.94%Strong BuyUnlock the MLYS analyst price target with TipRanks PremiumDE:1VT vs MLYSUnlock the MLYS top-analyst price target with TipRanks Premium
GPCRStructure Therapeutics, Inc. Sponsored ADR$20.88$1.56B-6.75-38.57%Strong BuyUnlock the GPCR analyst price target with TipRanks PremiumDE:1VT vs GPCRUnlock the GPCR top-analyst price target with TipRanks Premium
KLRAKailera Therapeutics, Inc.$12.14$1.67B-6.90-53.27%Strong BuyUnlock the KLRA analyst price target with TipRanks PremiumDE:1VT vs KLRAUnlock the KLRA top-analyst price target with TipRanks Premium
PBLSParabilis Medicines, Inc.$27.30$3.50B-0.74-13.77%Strong BuyUnlock the PBLS analyst price target with TipRanks PremiumDE:1VT vs PBLSUnlock the PBLS top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%200%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
DE:1VTViking Therapeutics24.00-7.50-23.80%
NAMSNewAmsterdam Pharma Company19.56-17.44-47.14%
MLYSMineralys Therapeutics, Inc.15.55-23.62-60.30%
GPCRStructure Therapeutics, Inc. Sponsored ADR20.47-12.29-37.52%
KLRAKailera Therapeutics, Inc.12.15-13.85-53.27%
PBLSParabilis Medicines, Inc.27.25-4.35-13.77%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts